Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
67 hedge funds and large institutions have $30.5M invested in Zynerba Pharmaceuticals, Inc in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 15 reducing their positions, and 13 closing their positions.
168% more call options, than puts
Call options by funds: $8.36M | Put options by funds: $3.12M
60% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 15
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 66 → 67 (+1)
60% less capital invested
Capital invested by funds: $77M → $30.5M (-$46.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$2.11M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$1.42M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.38M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.15M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$685K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$6.66M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.85M |
| 3 |
JP Morgan Chase
New York
|
-$3.45M |
| 4 |
Citigroup
New York
|
-$2.29M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
76
GSA Capital Partners
London,
United Kingdom
| – | -$185K | -10,900 | Closed |
|
|
FMA
77
FNY Managed Accounts
New York
| – | -$127K | -7,500 | Closed |
|
78
Group One Trading
Chicago,
Illinois
| – | -$48.6K | -4,596 | Closed |
|
79
Creative Planning
Overland Park,
Kansas
| – | -$15K | -871 | Closed |
|
|
WVP
80
Worth Venture Partners
Fort Lee,
New Jersey
| – | -$1K | -43 | Closed |
|
ZYNE Hedge Fund Activity: Q3 2017 in Review
67 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2017, worth a combined $30.5M — down 60% from $77M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ZYNE positions and 13 closed out — a net gain of 2 holders — while 24 added to existing stakes and 15 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $2.11M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $6.66M sold.
- 67 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2017, up from 66 in Q2 2017.
- Funds reported $30.5M of Zynerba Pharmaceuticals, Inc stock for Q3 2017, down 60% quarter-over-quarter.
- 15 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2017 and 13 closed out, a net change of +2 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2017 was RTW Investments, an estimated $2.11M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2017 was Marshall Wace North America, an estimated $6.66M sold.
Based on aggregated 13F filings for Q3 2017.